Brief: Advicenne Expects Imminent Marketing Authorization For ADV7103 (Sibnayal™) For dRTA In Europe

Advicenne SA

19/03/2021 17:19

March 19 (Reuters) - Advicenne SA  ADVIC.PA :
    * ADVICENNE EXPECTS IMMINENT MARKETING AUTHORIZATION FOR
ADV7103
(SIBNAYAL™) FOR DRTA IN EUROPE
    * WITHDRAWS ORPHAN DRUG DESIGNATION APPLICATION TO
ACCELERATE
AVAILABILITY FOR PATIENTS
    * WILL BE ABLE TO MAKE ADV7103 AVAILABLE TO PATIENTS
SUFFERING
FROM DRTA IN EUROPE IN SHORTEST POSSIBLE TIMEFRAME

Source text for Eikon:  ID:nBw4zxyt0a 
Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))